GSK plc (NYSE:GSK) Receives $50.00 Average Price Target from Analysts

GSK plc (NYSE:GSK) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $50.00.

A number of research analysts recently commented on the company. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Citigroup raised GSK to a “strong-buy” rating in a research note on Monday, June 24th. The Goldman Sachs Group began coverage on shares of GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Finally, Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GSK. Register Financial Advisors LLC acquired a new stake in shares of GSK in the first quarter valued at about $31,000. BKM Wealth Management LLC acquired a new stake in GSK during the 4th quarter valued at approximately $32,000. Richardson Financial Services Inc. acquired a new stake in GSK during the 4th quarter valued at approximately $40,000. Newbridge Financial Services Group Inc. bought a new position in GSK during the 1st quarter worth approximately $49,000. Finally, Triad Wealth Partners LLC acquired a new position in shares of GSK in the 2nd quarter worth approximately $49,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

NYSE GSK opened at $39.40 on Tuesday. The firm has a 50-day moving average price of $41.27 and a two-hundred day moving average price of $41.43. GSK has a 12-month low of $33.67 and a 12-month high of $45.92. The company has a market capitalization of $81.66 billion, a P/E ratio of 14.28, a P/E/G ratio of 1.20 and a beta of 0.64. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion for the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. Analysts anticipate that GSK will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Friday, May 17th were paid a $0.3762 dividend. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend was Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.82%. GSK’s payout ratio is currently 54.71%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.